Future R&D And Facility Expansion Will Introduce New Products In Pet Care And Pharmaceuticals

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

16 Mar 25

Updated

25 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

9.5%

7D

-1.4%

Loading

1Y

9.5%

7D

-1.4%

You can edit this narrative until Nov 26 11:10 AM. Then, changes will post as Updates.

Author's Valuation

€403.211.6% undervalued

AnalystConsensusTarget Fair Value

Shared on 25 Nov 25

VIRP: Accelerated Regional Momentum Will Sustain an Upgraded Bullish Outlook for 2025

Analysts have raised Virbac's price target from €390 to €415, citing accelerated growth across all regions as the key driver for their more positive outlook. Analyst Commentary Bullish Takeaways Bullish analysts cite a clear acceleration in Virbac's growth across all geographic regions, which supports a more positive outlook for the company.

Shared on 07 Nov 25

Fair value Increased 1.41%

VIRP: Accelerated Regional Expansion Will Drive Upgraded Earnings Outlook Next Year

Narrative Update on Virbac Analysts have raised Virbac's price target from €398 to €403, citing accelerated growth across all regions as the primary driver for this upward revision. Analyst Commentary The most recent research notes reflect increased optimism around Virbac's trajectory, with upward revisions to both rating and price targets.

Shared on 01 May 25

Fair value Increased 7.79%

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 0.14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Increased 0.14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Decreased 4.64%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

€403.2

11.6% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

5.28%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.18%

Calculation

€204.30m

Earnings '28

x

18.90x

PE Ratio '28

=

€3.86b

Market Cap '28

€3.86b

Market Cap '28

/

8.39m

No. shares '28

=

€460.37

Share Price '28

€460.37 Share Price '28

Discounted to 2025 @ 6.18% p.a.

=

€384.57

Fair Value '25